Effects of berberine on blood glucose in patients with type 2 diabetes mellitus: a systematic literature review and a meta-analysis

Abstract

We conducted a systematic review and meta-analysis to evaluate the effect of Berberine on glucose in patients with type 2 diabetes mellitus and identify potential factors may modifying the hypoglycemic effect. We searched PubMed, Embase, the Cochrane Library, China National Knowledge Infrastructure, and Wanfang Database to identify randomized controlled trials that investigated the effect of Berberine. We calculated weighted mean differences (WMD) and 95% confidence interval (CI) for fasting plasma glucose (FPG), postprandial plasma glucose (PPG) and glycated haemoglobin (HbA1c) levels. Twenty-eight studies were identified for analysis, with a total of 2,313 type 2 diabetes mellitus (T2DM) patients. The pool data showed that Berberine treatment was associated with a better reduction on FPG (WMD =-0.54 mmol/L, 95% CI:-0.77 to-0.30), PPG (WMD =-0.94 mmol/L, 95% CI:-1.27 to-0.61), and HbA1c (WMD =-0.54 mmol/L, 95% CI:-0.93 to-0.15) than control groups. Subgroup-analyses indicated that effects of Berberine on blood glucose became unremarkable as the treatment lasted more than 90 days, the daily dosage more than 2 g/d and patients aged more than 60 years. The efficiency of Berberine combined with hypoglycaemics is better than either Berberine or hypoglycaemic alone. The dosage and treatment duration of Berberine and patients' age may modify the effect.

Berberine for prevention of dementia associated with diabetes and its comorbidities: A systematic review

“…Berberine-containing plants have historically been used to treat gastrointestinal complications such as diarrhea and dysentery [17,18], and berberine's antimicrobial activity has been wellcharacterized [17,19]. However, in recent years, the focus of berberine research has shifted towards potential therapeutic benefits in treating metabolic dysfunctions, such as T2DM, with data indicating glucose-and lipid-lowering effects [20,21]. Clinical evidence suggests that berberine significantly reduces fasting and postprandial plasma glucose, glycosylated hemoglobin A1c, serum cholesterol, triglycerides and low-density lipoprotein cholesterol (LDL-C) in T2DM patients [22,23].…”

“…Clinical evidence suggests that berberine significantly reduces fasting and postprandial plasma glucose, glycosylated hemoglobin A1c, serum cholesterol, triglycerides and low-density lipoprotein cholesterol (LDL-C) in T2DM patients [22,23]. Therapeutic benefits of berberine in treating T2DM and metabolic syndrome (MetS) have been reviewed previously [20,21,24]. In addition, preclinical evidence suggests that berberine has neuroprotective activities [25,26].…”

Recent Advances in Berberine Inspired Anticancer Approaches: From Drug Combination to Novel Formulation Technology and Derivatization

“…The diversity of berberine's effect and potential to treat numerous diseases has been extensively reviewed and include antibacterial [14], anti-inflammatory [15] antidiabetic [16], antiobesity [17] and antidementia [18] effects. The best way to explain these effects is of course the polypharmacology principle of action, which is evident for multifunctional natural products like berberine [19].…”

“…The best way to explain these effects is of course the polypharmacology principle of action, which is evident for multifunctional natural products like berberine [19]. As with other diseases, the therapeutic potential of berberine for cancer is also mediated through effect on diverse The diversity of berberine's effect and potential to treat numerous diseases has been extensively reviewed and include antibacterial [14], anti-inflammatory [15] antidiabetic [16], antiobesity [17] and antidementia [18] effects. The best way to explain these effects is of course the polypharmacology principle of action, which is evident for multifunctional natural products like berberine [19].…”

Coptisine fromCoptis chinensisexerts diverse beneficial properties: A concise review

“…Processed CC products are reported to exert ameliorative effect on severe skin disease, dysentery, gastroenteritis and diabetes, etc Structure‐activity research draw a conclusion that isoquinoline alkaloids in CC, namely berberine, coptisine, palmatine, epiberberine and jatrorrhizine, are the main constituents responsible for its bioactive properties . By far, numerous systematic reviews have led to a summing‐up that berberine, the most in‐depth studied alkaloid of CC, exerts potent pharmacological efficacy in the treatment to mood disorders, tumour, type 2 diabetes mellitus, nerve damage as well as cardiovascular, hepatic and renal disorders . As the second most abundant isoquinoline alkaloid in CC, coptisine shares a same parent nucleus with berberine .…”